The FDA's Role in GLP-1 Telehealth: What's Actually Regulated

The FDA's relationship with GLP-1 telehealth is complicated — and widely misunderstood. The agency doesn't regulate telehealth platforms directly, but it has enormous power over what medications they can offer and how they can market them. Here's a clear breakdown of what the FDA actually controls, what it doesn't, and what recent enforcement actions mean for patients.

What the FDA Regulates

FDA-approved medications. Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved GLP-1 medications. The FDA reviewed clinical trial data for safety, efficacy, and manufacturing quality before granting approval. When you get a brand-name GLP-1 through telehealth, you're getting the same FDA-approved product as from any pharmacy.

503B outsourcing facilities. These are compounding operations that register with the FDA and are subject to FDA inspection. They can produce compounded medications in larger batches without individual prescriptions, but they must follow current Good Manufacturing Practices (cGMP). The FDA maintains a public list of registered 503B facilities.

Drug marketing and advertising. This is where the FDA has been most active in 2026. The Federal Food, Drug, and Cosmetic Act (FDCA) prohibits the introduction of "misbranded" drugs into interstate commerce. When telehealth companies market compounded GLP-1 products with claims that imply equivalence to FDA-approved drugs, or obscure the actual source of the medication, the FDA considers that misbranding.

What the FDA Does Not Regulate

Telehealth platforms themselves. The FDA does not license, certify, or regulate telehealth companies as entities. A telehealth platform's clinical practices, pricing, customer service, and business operations fall under state medical board oversight, state boards of pharmacy, and general consumer protection law — not the FDA.

503A compounding pharmacies. These pharmacies — which produce compounded medications based on individual prescriptions — are regulated primarily by state boards of pharmacy, not the FDA. The FDA has limited authority over 503A pharmacies unless they cross certain thresholds (like operating as de facto manufacturers without 503B registration).

The practice of medicine. The FDA does not regulate how a physician, NP, or PA prescribes medication. Prescribing decisions are governed by state medical boards and the standard of care established by medical professional organizations. If a telehealth prescriber writes an inappropriate GLP-1 prescription, the enforcement mechanism is the state medical board, not the FDA.

The 2026 Enforcement Wave

The FDA's enforcement against GLP-1 telehealth companies escalated dramatically in early 2026. The timeline tells the story.

In September 2025, the FDA sent over 55 warning letters to online sellers of compounded GLP-1 products for misleading direct-to-consumer advertising. At the time, many industry observers considered it largely performative — the letters had little immediate effect on market behavior.

On February 6, 2026, the FDA announced it would take "decisive steps" to restrict the active pharmaceutical ingredients (APIs) used in compounded GLP-1 products and combat misleading marketing. The agency explicitly warned that entities manufacturing, distributing, or marketing unapproved compounded GLP-1 products could face "seizure and injunction" without further notice.

Three days later, Novo Nordisk sued Hims & Hers for patent infringement, alleging the telehealth company was mass-compounding injectable semaglutide using "inauthentic API." By March 9, the two companies settled — Hims & Hers agreed to offer Novo Nordisk's branded products (Ozempic and Wegovy) on its platform and to cease advertising compounded GLP-1 drugs except where medically necessary.

On March 3, 2026, the FDA issued 30 more warning letters to telehealth companies. The violations centered on two themes: implying that compounded products were the same as FDA-approved drugs, and obscuring product sourcing by marketing under the telehealth company's own brand without disclosing the compounding pharmacy.

What This Means for Patients

The FDA enforcement is primarily about marketing — not about whether compounded GLP-1 medications will remain available. Compounding under Section 503A of the FDCA remains legal when done pursuant to individual prescriptions by state-licensed pharmacies. The FDA is targeting mass-marketing practices, not the fundamental legal framework for patient-specific compounding.

That said, the regulatory environment is tightening. Patients currently using compounded GLP-1 medications should be aware that their provider's business model may change as enforcement increases. Platforms that rely heavily on marketing claims that violate FDA guidance may face operational disruptions.

The practical takeaway: choose providers that are transparent about pharmacy sourcing, don't make equivalence claims between compounded and FDA-approved products, and have a track record of regulatory compliance.